< Back to latest news & events

Event

9th Annual Translational Microbiome Conference

March 2024

Partner and Patent Attorney Craig Thomson will be speaking at the upcoming 9th Annual Translational Microbiome Conference in Boston, US on the 25th March 2024.

This event will continue to focus and build on the challenges and hurdles that companies working in the microbiome space will have to recognise and navigate to successfully commercialise their products.

As part of this, Craig’s session will explore ‘Building a Commercially Relevant IP Strategy for Investment and Beyond.’

We hope to see you there! Click the button below to find out more.

FIND OUT MORE

Attendees

Craig
Thomson

Latest updates

Happy World IP Day!

This year’s theme is ‘IP and the SDGs: Building our common future with innovation and creativity’. At HGF we are committed to supporting our clients in sustainable technologies and routinely …

Read article

IP Ingredients, Part 12: Exploring colours in the food & drink sector – overcoming hurdles and leveraging colour trade marks

We will all recognise as consumers an instance of when we used the colour of a product or its packaging to identify a specific brand that we wanted to buy …

Read article

Medical 3D Technologies: From Scanning to Printing

When we think of 3D technologies, we often think of 3D printing, which, as discussed later, has seen rapid advances in recent years. However, a sometimes overlooked area of medical …

Read article

Opinion Piece: Unitary Patent and Unified Patent Court in Ireland

Intellectual Property (IP) is a core part of any business and particularly is a vital part of the strategic toolkit for any business that creates value through innovation and constant …

Read article

IP Ingredients Blog, Parts 11-20

Welcome to our blog series, IP Ingredients, created by our Food & Drink Team. This blog will explore the latest IP news, updates, and discussions in the food & drink …

Read article

EnteroBiotix Limited Secures £27m Financing Round to Advance Clinical Trials

We are pleased to congratulate EnteroBiotix, on their milestone in their journey towards revolutionising healthcare for patients battling gut-related ailments. The leading clinical-stage biotechnology company has successfully closed a £27 …

Read article
See all updates